Q.-D. Nguyen

This study identifies de novo pyrimidine synthesis as a therapeutic target in IDH mutant gliomas, showing that DHODH inhibitors are effective in preclinical models.

This paper identifies a druggable metabolic vulnerability in diffuse midline glioma through a CRISPR screen, showing that inhibition of DHODH reduces pyrimidine biosynthesis and extends survival in mouse models.

The paper shows that FGFR inhibitors cause SWI/SNF complex dismissal from YAP-dependent enhancers, leading to adaptive resistance in TNBC through epigenetic and metabolic changes.